Document Detail


Therapy for early reperfusion after stroke.
MedLine Citation:
PMID:  17122798     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ischemic stroke is a leading cause of death and disability in the Western world. At present, intravenous administration of tissue plasminogen activator within 3 h of symptom onset is the only proven effective treatment to re-establish cerebral blood flow in the case of acute vessel occlusion. Unfortunately, few patients presenting with acute ischemic stroke qualify for intravenous tissue plasminogen activator therapy. The focus of current research is, therefore, to find new treatment options by which to obtain early reperfusion, and to extend the therapeutic window for intervention beyond 3 h. The purpose of this Review is to provide an integrated view of the current state of reperfusion therapy in patients with acute stroke, including pharmacologic agents and the methods of delivery. The focus will be on intravenous and intra-arterial use of plasminogen activators in acute supratentorial infarction. Other therapies, such as antiplatelet agents (i.e. glycoprotein IIb/IIIa inhibitors), and anticoagulant drugs will be discussed briefly.
Authors:
Eric Juttler; Martin Kohrmann; Peter D Schellinger
Related Documents :
17345048 - Neurological and functional recovery in human stroke are associated with peripheral blo...
16084148 - Management of risk in peripheral artery disease: recent therapeutic advances.
16128878 - Stroke and pulmonary thromboembolism after a long flight.
16505298 - Left insular stroke is associated with adverse cardiac outcome.
17038138 - Does rv lead positioning provide additional benefit to cardiac resynchronization therap...
18299298 - Cause-specific mortality of dialysis patients after coronary revascularization: why don...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Nature clinical practice. Cardiovascular medicine     Volume:  3     ISSN:  1743-4300     ISO Abbreviation:  -     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-11-23     Completed Date:  2006-12-15     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  101226507     Medline TA:  Nat Clin Pract Cardiovasc Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  656-63     Citation Subset:  IM    
Affiliation:
Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany. eric.juettler@med.uni-heidelberg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use
Aspirin / therapeutic use
Brain Ischemia / diagnosis,  drug therapy*,  physiopathology
Cerebrovascular Circulation* / drug effects
Diffusion Magnetic Resonance Imaging
Drug Administration Schedule
Drug Therapy, Combination
Embolectomy / methods
Fibrinolytic Agents / administration & dosage,  therapeutic use*
Heparin / therapeutic use
Humans
Infusions, Intra-Arterial
Infusions, Intravenous
Plasminogen Activators / administration & dosage,  therapeutic use*
Platelet Aggregation Inhibitors / therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Randomized Controlled Trials as Topic
Recombinant Proteins / therapeutic use
Reperfusion / methods
Streptokinase / administration & dosage,  therapeutic use
Stroke / diagnosis,  drug therapy*,  physiopathology
Tissue Plasminogen Activator / therapeutic use
Tomography, X-Ray Computed
Ultrasonography, Doppler, Transcranial
Urokinase-Type Plasminogen Activator / therapeutic use
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 50-78-2/Aspirin; 9005-49-6/Heparin; 99149-95-8/saruplase; EC 3.4.-/Streptokinase; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.68/Tissue Plasminogen Activator; EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lenticulostriate vasculopathy in twin-to-twin transfusion syndrome.
Next Document:  Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.